Epic Watch of the day: https://t.co/uq1ZAr50Ft

Bet you won't find a simpler explanation anywhere.

What are Monoclonal Anti-bodies? interesting to understand to get the trend for businesses like Syngene and other contract manufacturers+Animal Pharma innovators

@nivin27 Kenneth Andrade & all his interviews ever

Once invested it's your duty to look for Anti Thesis pointers/disconfirming evidence. Don't get caught up in echo chambers. Investing is lonely because of this

Let's Understand why Narrative is important in investing and how to create a Thesis that can help you to hold a stock in spite of the market environments

Time for a thread with international and Indian examples, Please retweet so that everyone can benefit 🧵🧵🧵🧵

The world we see and defined is given meaning by the words we choose to use. In short, the world is what we make of it. Something similar applies to creating a thesis before investing in a stock. Your thesis is what makes you hold a stock thick and through in spite of bull/bear

Example 1: Amazon- In May 1997, Amazon became a publically listed business. The target price set by analysts was $18 per share. It finished its first day at $23 per share. (So much for targets). In 1999, in the middle of the tech bubble. Same stock was trading at $100 per share.

Analysts were giving targets of $300 per share. However, after the collapse of the bubble many internet businesses went bust, but Amazon survived in spite of a 78% drop from 1999 highs. As we all know, Price changes perception. Same analysts started claiming it was massively

overpriced and claimed its days were "numbered". By the end of 2002, it was trading at 90times cash flow (so much for multiples to account for future)

The Q4F22 Earnings season is almost here!

What are the Key things that you need to track in various businesses like Hospitals 🏥, Pharma🩹, Chemicals 🧪 and Music🎵 etc ⤵️⤵️

I will be analysing the companies and the expectations in two ways:-

1⃣What does the company do and the sales split?
2⃣What to expect from the results/Business direction?

1. Divis Labs:

Over the years Divis has proven its capabilities as an API player and has the highest Ebitda margins (44%) when compared to the other Pharma companies. 57% of the business in the last Quarter Q3FY22 was contributed by Synthesis and 43% by Generic API’s.

What to expect?

Molnupiravir has contributed to almost 21% of sales for Divis in FY22 (According to Kotak).
Investors will need to track the recovery in the Generic API division which has been soft for the last 3 quarters and growth in CDMO ex of Molnupiravir.

What to look for in Financials?

Key monitorable to track is by how much the topline grows or degrows QoQ. Given the base was high in last Quarter due to Molnupiravir Sales.

Topline sustaining above 2100 crores and margins above 41% will be good!

Out of 17 stocks that I own, I am allowed to go wrong in 2-3 of them. Not going wrong shows that you are not taking enough risks or operating on the edge. Learning from mistakes is the number 1 way to improve as an investor. An excerpt from the annual letter :)

Syngene - a long route opened. 1%*3 PnF

@Trader7Cool #Syngene Probable Triple Top Buy in 1%

Mega Thread: Jan-Jun 2021

26 Weeks, 26 Ideas, 26 Tweets

Days Gone 180. Efforts 360

CREDIT ACCESS GRAMEEN

SUVEN PHARMA

NIPPON LIFE INDIA ASSET MANAGEMENT

HEIDELBERG CEMENT INDIA

Syngene:

For long term investors - Buy at any dips
PnF Chart (1%*3) Stop loss level - 570 (previous low O's below Anchor column)
Candlesticks Charts - 605 (below gap boundary)

below Anchor column breakout** (ABC)